The tumour necrosis factor receptor-associated periodic syndrome: Current concepts

Expert Reviews in Molecular Medicine

Volumn 7, Issue 22, 2005, Pages 1-18

  Stojanov, Silvia ^a   McDermott, Michael F ^b  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COLCHICINE; CORTICOSTEROID; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; PREDNISONE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

AMYLOIDOSIS; APOPTOSIS; BEHCET DISEASE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; EXON; FAMILIAL MEDITERRANEAN FEVER; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

ANIMALS; AUTOIMMUNE DISEASES; FAMILIAL MEDITERRANEAN FEVER; HUMANS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I;

EID: 32844473310     PISSN: 14623994     EISSN: 14623994     Source Type: Journal    
DOI: 10.1017/S1462399405009749     Document Type: Review

References (81)

1. McDermott, M.F. et al. (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97, 133-144, PubMed: 10199409
2. McDermott, M.F. and Aksentijevich, I. (2002) The autoinflammatory syndromes. Curr Opin Allergy Clin Immunol 2, 511-516, PubMed: 14752334
3. Hull, K.M. et al. (2002) The TNF receptor-associated periodic syndrome (TRAPS): Emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 81, 349-368, PubMed: 12352631
4. Palladino, M.A. et al. (2003) Anti-TNF-alpha therapies: The next generation. Nat Rev Drug Discov 2, 736-746, PubMed: 12951580
5. Black, R.A. et al. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385, 729-733, PubMed: 9034190
6. Locksley, R.M., Killeen, N. and Lenardo, M.J. (2001) The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 104, 487-501, PubMed: 11239407
7. McDermott, M.F. (2001) TNF and TNFR biology in health and disease. Cell Mol Biol (Noisy-legrand) 47, 619-635, PubMed: 11502070
8. Chan, F.K. et al. (2000) A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288, 2351-2354, PubMed: 10875917
9. Banner, D.W. et al. (1993) Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: Implications for TNF receptor activation. Cell 73, 431-445, PubMed: 8387891
10. Micheau, O. and Tschopp, J. (2003) Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114, 181-190, PubMed: 12887920
11. Legler, D.F. et al. (2003) Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation. Immunity 18, 655-664, PubMed: 12753742
12. Schneider-Brachert, W. et al. (2004) Compartmentalization of TNF receptor 1 signaling: Internalized TNF receptosomes as death signaling vesicles. Immunity 21, 415-428, PubMed: 15357952
13. Luberto, C. et al. (2002) Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J Biol Chem 277, 41128-41139, PubMed: 12154098
14. Zhang, S.Q. et al. (2000) Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity 12, 301-311, PubMed: 10755617
15. Bouwmeester, T. et al. (2004) A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol 6, 97-105, PubMed: 14743216
16. Wallach, D. et al. (1991) Soluble and cell surface receptors for tumor necrosis factor. Agents Actions Suppl 35, 51-57, PubMed: 1664189
17. Reddy, P. et al. (2000) Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 275, 14608-14614, PubMed: 10799547
18. Levine, S.J. et al. (2005) Proteasome Inhibition Induces TNFR1 Shedding from Human Airway Epithelial (NCI-H292) Cells. Am J Physiol Lung Cell Mol Physiol PubMed: 15821012
19. Cui, X. et al. (2002) Identification of ARTS-1 as a novel TNFR1-binding protein that promotes TNFR1 ectodomain shedding. J Clin Invest 110, 515-526, PubMed: 12189246
20. Hawari, F.I. et al. (2004) Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: A mechanism for generation of soluble cytokine receptors. Proc Natl Acad Sci U S A 101, 1297-1302, PubMed: 14745008
21. Williamson, L.M. et al. (1982) Familial Hibernian fever. Q J Med 51, 469-480, PubMed: 7156325
22. Tchernitchko, D. et al. (2005) Unexpected high frequency of P46L TNFRSF1A allele in sub-Saharan West African populations. Eur J Hum Genet 13, 513-515, PubMed: 15586174
23. Aksentijevich, I. et al. (2001) The tumor-necrosis-factor receptor-associated periodic syndrome: New mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 69, 301-314, PubMed: 11443543
24. Dode, C. et al. (2002) The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 46, 2181-2188, PubMed: 12209523
25. Aganna, E. et al. (2003) Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 48, 2632-2644, PubMed: 13130484
26. Kusuhara, K. et al. (2004) Tumour necrosis factor receptor-associated periodic syndrome with a novel mutation in the TNFRSF1A gene in a Japanese family. Eur J Pediatr 163, 30-32, PubMed: 14610673
27. Stojanov, S. et al. (2004) Periodic fever due to a novel TNFRSF1A mutation in a heterozygous Chinese carrier of MEFV E148Q. Rheumatology (Oxford) 43, 526-527, PubMed: 15024140
28. Sarrauste de Menthiere, C. et al. (2003) INFEVERS: The Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 31, 282-285, PubMed: 12520003
29. Touitou, I. et al. (2004) Infevers: An evolving mutation database for auto-inflammatory syndromes. Hum Mutat 24, 194-198, PubMed: 15300846
30. Kriegel, M.A. et al. (2003) Tumor necrosis factor receptor-associated periodic syndrome characterized by a mutation affecting the cleavage site of the receptor: Implications for pathogenesis. Arthritis Rheum 48, 2386-2388, PubMed: 12905494
31. Arostegui, J.I. et al. (2005) Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associated periodic syndrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response. Eur J Pediatr 164, 13-16, PubMed: 15549379
32. Aganna, E. et al. (2002) An Israeli Arab patient with a de novo TNFRSF1A mutation causing tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 46, 245-249, PubMed: 11817598
33. Kallinich, T. et al. (2004) Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis. J Rheumatol 31, 2519-2522, PubMed: 15570662
34. Aganna, E. et al. (2004) Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun 5, 289-293, PubMed: 15071491
35. Obici, L. et al. (2002) Molecular characterization of tumor necrosis factor receptor associated periodic syndrome (TRAPS) in Italy: identification of novel and recurrent mutations and evidence for a high frequency of the R92Q allele in the Italian population. Third International conference on FMF and hereditary inflammatory disorders, La Grande Motte, France. http://congres.igh.cnrs.fr/FMF2002/ abstractVISU.pl?action=web&FMFid=A32
36. Minden, K. et al. (2004) Tumour necrosis factor receptor associated periodic syndrome (TRAPS) with central nervous system involvement. Ann Rheum Dis 63, 1356-1357, PubMed: 15361406
37. Ida, H. et al. (2004) A novel mutation (T61I) in the gene encoding tumour necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus. Rheumatology (Oxford) 43, 1292-1299, PubMed: 15280569
38. Horiuchi, T. et al. (2004) Novel mutations in TNFRSF1A in patients with typical tumor necrosis factor receptor-associated periodic syndrome and with systemic lupus erythematosus in Japanese. Int J Mol Med 14, 813-818, PubMed: 15492850
39. Pinckard, J.K. et al. (1997) Constitutive shedding of both p55 and p75 murine TNF receptors in vivo. J Immunol 158, 3869-3873, PubMed: 9103455
40. Diez-Ruiz, A. et al. (1995) Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 54, 1-8, PubMed: 7859870
41. Lantz, M. et al. (1990) Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 2, 402-406, PubMed: 2129506
42. Jansen, J. et al. (1995) Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-alpha antibody. J Clin Immunol 15, 45-50, PubMed: 7759600
43. Xanthoulea, S. et al. (2004) Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med 200, 367-376, PubMed: 15289505
44. Huggins, M.L. et al. (2004) Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: Differences between cell types. Arthritis Rheum 50, 2651-2659, PubMed: 15334481
45. Siebert, S. et al. (2005) Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant. Arthritis Rheum 52, 1287-1292, PubMed: 15818692
46. Todd, I. et al. (2004) Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour. Immunology 113, 65-79, PubMed: 15312137
47. Storey, H. et al. (2002) The p55 tumour necrosis factor receptor TNFR1 contains a trans-Golgi network localization signal in the C-terminal region of its cytoplasmic tail. Biochem J 366, 15-22, PubMed: 11985495
48. Yousaf, N. et al. (2005) TNF-R1 from periodic syndrome patients interact with wild-type TNF-R1 inducing TNF-independent NF-κB activation. Arthritis Rheum 52, 2906-2916
49. Arkwright, P.D. et al. (2002) Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin Exp Immunol 130, 484-488, PubMed: 12452839
50. Trost, S. and Rose, C.D. (2005) Myocarditis and sacroiliitis: 2 previously unrecognized manifestations of tumor necrosis factor receptor associated periodic syndrome. J Rheumatol 32, 175-177, PubMed: 15630744
51. Lamprecht, P. et al. (2004) Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis 63, 1518-1520, PubMed: 15479908
52. Saulsbury, F.T. and Wispelwey, B. (2005) Tumor necrosis factor receptor-associated periodic syndrome in a young adult who had features of periodic fever, aphthous stomatitis, pharyngitis, and adenitis as a child. J Pediatr 146, 283-285, PubMed: 15689926
53. Amoura, Z. et al. (2005) Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behcet's disease. Arthritis Rheum 52, 608-611, PubMed: 15692984
54. Stojanov, S. et al. (2004) Molecular analysis of the MVK and TNFRSF1A genes in patients with a clinical presentation typical of the hyperimmunoglobulinemia D with periodic fever syndrome: A low-penetrance TNFRSF1A variant in a heterozygous MVK carrier possibly influences the phenotype of hyperimmunoglobulinemia D with periodic fever syndrome or vice versa. Arthritis Rheum 50, 1951-1958, PubMed: 15188372
55. Hoffmann, F. et al. (2005) Identification of a novel mevalonate kinase gene mutation in combination with the common MVK V377I substitution and the low-penetrance TNFRSF1A R92Q mutation. Eur J Hum Genet 13, 510-512, PubMed: 15657603
56. Touitou, I., Notarnicola, C. and Grandemange, S. (2004) Identifying mutations in autoinflammatory diseases: Towards novel genetic tests and therapies? Am J Pharmacogenomics 4, 109-118, PubMed: 15059033
57. Gunther, P. et al. (2005) [Tumour necrosis factor receptor-associated periodic syndrome Seltene Differenzialdiagnose der Multiplen Sklerose.]. Nervenarzt PubMed: 15834693
58. Rösen-Wolff, A. et al. (2001) Periodic fever (TRAPS) caused by mutations in the TNFalpha receptor 1 (TNFRSF1A) gene of three German patients. Eur J Haematol 67, 105-109, PubMed: 11722598
59. Gimenez, M.A., Sim, J.E. and Russell, J.H. (2004) TNFR1-dependent VCAM-1 expression by astrocytes exposes the CNS to destructive inflammation. J Neuroimmunol 151, 116-125, PubMed: 15145610
60. Magnano, M.D., Robinson, W.H. and Genovese, M.C. (2004) Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol 22, S134-140, PubMed: 15552527
61. (2003) Enbrel® (etanercept) Prescribing Information, Immunex Corporation. http://www.fda.gov/medwatch/safety/1999/enbrelpre.htm
62. Kastner, D.L., Aksentijevich, I. and Galon, J. (1999) TNF receptor associated periodic syndrome (TRAPS): Novel TNFR1 mutations and early experience with etanercept therapy. Arthritis Rheum 42, S117
63. Galon, J. et al. (2000) TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 12, 479-486, PubMed: 10899034
64. Simon, A. et al. (2001) Genetic analysis as a valuable key to diagnosis and treatment of periodic Fever. Arch Intern Med 161, 2491-2493, PubMed: 11700162
65. Nigrovic, P.A. and Sundel, R.P. (2001) Treatment of TRAPS with etanercept: Use in pediatrics. Clin Exp Rheumatol 19, 484-485, PubMed: 11491520
66. Hull, K.M., Kastner, D.L. and Balow, J.E. (2002) Hereditary periodic fever. N Engl J Med 346, 1415-1416; author reply 1415-1416, PubMed: 11986423
67. Hull, K.M. et al. (2002) Efficacy of etanercept for the treatment of patients with TNF receptor-associated periodic syndrome (TRAPS). Arthritis Rheum 46, S378
68. Drewe, E. et al. (2003) Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): Clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford) 42, 235-239, PubMed: 12595616
69. Weyhreter, H. et al. (2003) A new mutation causing autosomal dominant periodic fever syndrome in a Danish family. J Pediatr 142, 191-193, PubMed: 12584543
70. Broeders, E.N. et al. (2004) A novel mutation of tumor necrosis factor receptor alpha type 1 associated with TRAPS and amyloidosis. Am J Med Genet A 128, 331, PubMed: 15216558
71. Simon, A. et al. (2004) Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med 117, 208-210, PubMed: 15300976
72. Derk, C.T. and DeHoratius, R.J. (2003) Tuberculous tonsillitis in a patient receiving etanercept treatment. Ann Rheum Dis 62, 372, PubMed: 12634245
73. Manadan, A.M., Block, J.A. and Sequeira, W. (2003) Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol 21, 526, PubMed: 12942713
74. Toussirot, E. and Wendling, D. (2004) The use of TNF-alpha blocking agents in rheumatoid arthritis: An overview. Expert Opin Pharmacother 5, 581-594, PubMed: 15013927
75. Cerquaglia, C. et al. (2005) Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: An update. Curr Drug Targets Inflamm Allergy 4, 117-124, PubMed: 15720245
76. Aganna, E. et al. (2001) Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Dutch family: Evidence for a TNFRSF1A mutation with reduced penetrance. Eur J Hum Genet 9, 63-66, PubMed: 11175303
77. Nevala, H. et al. (2002) A novel mutation in the third extracellular domain of the tumor necrosis factor receptor 1 in a Finnish family with autosomal-dominant recurrent fever. Arthritis Rheum 46, 1061-1066, PubMed: 11953985
78. Drewe, E. and Powell, R.J. (2002) Novel treatment for tumour necrosis factor receptor associated periodic syndrome (TRAPS): Case history of experience with infliximab and sirolimus post etanercept. Third International conference on FMF and hereditary inflammatory disorders, La Grande Motte, France. http://congres.igh.cnrs.fr/FMF2002/ abstractVISU.pl?action=web&FMFid=A6
79. O'Hara, R. et al. (2004) Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum 50, 1788-1799, PubMed: 15188355
80. Migita, K. et al. (1998) Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts. Lab Invest 78, 535-539, PubMed: 9605178
81. Stix, B. et al. (2001) Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1, -2, and -3. Am J Pathol 159, 561-570, PubMed: 11485914